In this Issue
Sergey Brin Bets $15M on Ibogaine Startup Soneira, But Questions Loom Over Patents
Head-to-Head Trial Hopes to Assess Role of Psychotherapy in Psilocybin Treatment
J&J Seeks FDA Approval of Spravato as Monotherapy
Other Stories
***
Google co-founder and psychedelics dabbler Sergey Brin looks set to fill $15M of a $25M round by ibogaine biotech Soneira Bio, which hopes to develop the drug for traumatic brain injury (TBI). Murmurings of the startup and its potential suitors have been doing the rounds for more than a year, with excitement abounding among the likes of the Jurvetsons and Brin.
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Subscribe AnnuallySubscribe Monthly
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space✓ Regular articles and deep dives across psychedelic research, policy and business✓ Interviews with insiders✓ Monthly interactive database and commentary on psychedelic patents✓ Quick-take analysis of major developments✓ A Library of primers and explainers✓ Access to our full back catalogue
Learn more about Pα+
